T1	Participants 576 829	71 patients (1981-1983) compared the association of CYC with corticosteroids (CS) and PE to CS and PE, in order to evaluate the efficacy of CYC given as the first-line treatment to control disease activity and subsequent survival of PAN and CSS patients
T2	Participants 1002 1033	78 patients without HBV markers
T3	Participants 1124 1159	33 patients with PAN related to HBV
T4	Participants 1470 1535	56 patients and addressed to severe PAN without HBV markers or CS
